C12N 9/6456
Plasminogen activators
Official title: {Plasminogen activators}
C12N9/6456 (Plasminogen activators) appears on 568 US grants and 236 published applications in this corpus.
Search patents in C12N- Granted patents
- 568
- Published applications
- 236
- Assignees
- 254
- Inventors
- 1,028
- Latest grant
- 14 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 5 | 0 |
| 1977 | 5 | 0 |
| 1978 | 3 | 0 |
| 1979 | 4 | 0 |
| 1980 | 4 | 0 |
| 1981 | 10 | 0 |
| 1982 | 8 | 0 |
| 1983 | 2 | 0 |
| 1984 | 1 | 0 |
| 1985 | 15 | 0 |
| 1986 | 5 | 0 |
| 1987 | 6 | 0 |
| 1988 | 8 | 0 |
| 1989 | 9 | 0 |
| 1990 | 26 | 0 |
| 1991 | 32 | 0 |
| 1992 | 36 | 0 |
| 1993 | 34 | 0 |
| 1994 | 20 | 0 |
| 1995 | 22 | 0 |
| 1996 | 28 | 0 |
| 1997 | 39 | 0 |
| 1998 | 38 | 0 |
| 1999 | 28 | 0 |
| 2000 | 14 | 0 |
| 2001 | 14 | 2 |
| 2002 | 10 | 14 |
| 2003 | 14 | 23 |
| 2004 | 12 | 25 |
| 2005 | 13 | 16 |
| 2006 | 18 | 14 |
| 2007 | 6 | 10 |
| 2008 | 7 | 6 |
| 2009 | 2 | 15 |
| 2010 | 6 | 6 |
| 2011 | 4 | 5 |
| 2012 | 6 | 10 |
| 2013 | 3 | 8 |
| 2014 | 7 | 9 |
| 2015 | 4 | 11 |
| 2016 | 3 | 3 |
| 2017 | 5 | 7 |
| 2018 | 3 | 5 |
| 2019 | 5 | 4 |
| 2020 | 1 | 7 |
| 2021 | 2 | 3 |
| 2022 | 7 | 5 |
| 2023 | 4 | 7 |
| 2024 | 1 | 8 |
| 2025 | 5 | 8 |
| 2026 | 4 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Protease substrate, and polypeptide including protease cleavage sequence14 Jul 2026US 12,680,093 B2Chugai Seiyaku Kabushiki Kaisha
- PD1-based vaccination composition and methods thereof2 Jun 2026US 12,642,845 B2Versitech Limited
- 177-Lu labeled peptide for site-specific uPAR-targeting31 Mar 2026US 12,589,171 B2TRT Innovations APS
- Methods for safe and effective thrombolysis using sequential administration of tissue plasminogen activator and mutant pro-urokinase31 Mar 2026US 12,590,301 B2Thrombolytic Science, Inc.
- Fusion protein suitable for dissolving fibrin clot, and pharmaceutical composition containing said fusion protein30 Dec 2025US 12,509,507 B2National Cancer Center
- Method for the Production of Pharmaceutically Active Recombinant Human Low Molecular Weight Urokinase8 Oct 2026US 2026/0308654 A1Cerbios-Pharma SA
- Antibody binding to fibrin, fibrinolytic protein containing antibody, and pharmaceutical formulation containing protein27 Aug 2026US 2026/0250366 A1Rin Institute Inc.
- Targeting and lysing microthrombi associated with aberrant blood clotting7 May 2026US 2026/0125665 A1
- suPAR and Prediction and Treatment of Acute Kidney Injury12 Mar 2026US 2026/0070973 A1Emory University
- Thrombolytic and neuro/vasculoprotective nanoconjugates8 Jan 2026US 2026/0007614 A1The Cleveland Clinic Foundation
Most cited
By later US patents
- Plasminogen activator derivatives616US 4,640,835 ANippon Chemiphar Co., Ltd. · 1987
- Isolation of exogenous recombinant proteins from the milk of transgenic mammals500US 4,873,316 ABiogen, Inc. · 1989
- Method for dominant selection in eucaryotic cells277US 5,122,464 ACelltech Limited, a British Company · 1992
- Purification and activity assurance of precipitated heterologous proteins229US 4,511,503 AGenentech, Inc. · 1985
- Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases229US 5,759,542 ANew England Deaconess Hospital Corporation · 1998